01295nas a2200421   4500000000100000000000100001008004100002653001100043653003600054653002600090653008000116653004300196653001200239653002200251653002400273653003000297653001800327653003600345653003200381100001500413700001300428700001300441700001200454700001500466700001600481700001200497700001200509700001500521700001500536700001300551700001300564700001500577245021400592250001500806300001400821490000700835020003100842       2023                            d10aHumans10a*Glycopyrrolate/adverse effects10aRetrospective Studies10a*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology10aMuscarinic Antagonists/adverse effects10aEngland10aCOPD dual therapy10aLABA/LAMA new users10acomparative effectiveness10aexacerbations10aHealthcare resource utilization10asingle-inhaler dual therapy1 aG. Requena1 aA. Czira1 aV. Banks1 aR. Wood1 aT. Tritton1 aC. Castillo1 aJ. Yeap1 aR. Wild1 aC. Compton1 aK. Rothnie1 aF. Herth1 aJ. Quint1 aA. Ismaila00aComparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England  a2023/09/21  a2039-20540 v18  a1176-9106 (Print)1176-9106